Bortezomib-based Anthracycline-free Induction for Pediatric Relapsed ALL as a Bridge to Immunotherapy

Conclusion: Anthracyclines can be safely omitted from bortezomib-based therapies in patients with R/R ALL, when planning to proceed to immunotherapy.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Article Source Type: research